Skip to main content
PYXS
NASDAQ Life Sciences

Pyxis Q3 Loss Narrows to $20.0M; Cash Runway Extended Into 1H 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.65
Mkt Cap
$198.509M
52W Low
$1.03
52W High
$5.55
52W Position info
60% above low
Off High info
70% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

PYXS sits 60% above its 52-week low of $1.03.

Summary

Pyxis reported a narrower $20.0M Q3 loss and said cash plus October offering proceeds fund operations into the first half of 2028, covering the planned mid-2027 launch of its Phase 3 head and neck cancer trial.


Key Events · Earnings and Guidance · PYXS

  • Q3 Loss Narrows to $20.0M

    Net loss was $20.0M, or $0.24 per share, versus $22.0M, or $0.35 per share, a year earlier; R&D fell to $16.6M from $17.8M on lower manufacturing costs.

  • Runway Extended Into 1H 2028

    Cash, restricted cash and short-term investments totaled $57.0M at September 30, 2026; with net October offering proceeds, the company says it can fund operations into the first half of 2028.

  • Phase 3 Trial Set for Mid-2027

    The global Headliner SM trial will randomize approximately 500 patients 1:1 to MICVO or investigator's choice of cetuximab, docetaxel or methotrexate, with co-primary endpoints of overall response rate and overall survival.

  • FDA Dose Feedback Due Q1 2027

    FDA feedback on dose selection following the End-of-Phase 2 meeting is expected in the first quarter of 2027; updated monotherapy overall survival data is expected in the first half of 2027.


Analysis · PYXS · Life Sciences

The quarter itself was unremarkable: R&D fell to $16.6M from $17.8M and G&A dropped to $4.0M, cutting the net loss to $20.0M from $22.0M a year ago. What matters is the runway. With $57.0M of cash and securities at September 30 plus net proceeds from the October offering, operations are funded into the first half of 2028, past the planned mid-2027 start of the Phase 3 Headliner SM trial. The company also laid out a concrete regulatory path: FDA dose-selection feedback in Q1 2027, roughly 500 patients randomized 1:1 against investigator's choice of cetuximab, docetaxel or methotrexate, and co-primary endpoints of overall response rate and overall survival. Updated overall survival data from the monotherapy study is expected in the first half of 2027, and a December 2026 update will carry the first combination data with pembrolizumab in first-line disease.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PYXS was trading at $1.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $198.5M. The 52-week trading range was $1.03 to $5.55. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PYXS - Latest Insights

PYXS
Nov 19, 2026, 7:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.50
Real-time Price: $1.40 info
Change: -$0.100 (-7%) info
Market Cap: $167.451M info
PYXS
Nov 18, 2026, 6:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.46
Real-time Price: $1.40 info
Change: -$0.060 (-4%) info
Market Cap: $167.451M info
PYXS
Nov 13, 2026, 4:17 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.58
Real-time Price: $1.40 info
Change: -$0.180 (-11%) info
Market Cap: $167.451M info
PYXS
Nov 05, 2026, 7:45 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.65
Real-time Price: $1.40 info
Change: -$0.250 (-15%) info
Market Cap: $167.451M info
PYXS
Nov 05, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.65
Real-time Price: $1.40 info
Change: -$0.250 (-15%) info
Market Cap: $167.451M info